From 67% to 97%: That’s a big improvement

Point-of-sale edit upped % of Rx with <7 days supply

February 9, 2020

A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply

Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.

Short Acting Opioid Duration Edit Substantially Reduces Large Day Supply for Commercially Insured Opioid Naïve Members Compared to a Control Group without an Edit (Fall 2019)

Related news

Perspectives

November 29, 2023

Traditional Drug Pipeline Monthly Update: November 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Perspectives

November 29, 2023

Specialty Drug Pipeline Monthly Update: November 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Perspectives

November 16, 2023

2023 NHCAA Rewind – The Prime/MRx Special Investigations Unit is Prepped to Explore the Frontier of Fraud  

Earlier this month, the Prime Therapeutics/Magellan Rx (Prime/MRx) Special Investigations Unit (SIU) and…